Guest Editorial
In Korea, all citizens are automatically and mandatorily enrolled by the national health insurance policy supported by the government. Hospitals and clinics across the country are paid by the national medical insurance authority in accordance with the medical insurance reimbursement provisions established by the Health Insurance Review and Assessment Service. It is managed by the National Health Insurance Corporation. Both these institutions are controlled by the Ministry of Health and Welfare. The ministry examines and manages medical insurance measures. Although there are multiple tiers of coverage based on financial status, the majority basically falls into the co-pay system where 80% to 90% is covered by the insurance and the rest is paid by the patients themselves. It is ideal that this small part where national medical coverage is not covered, the people select from private insurance companies that provide them with additional benefits. 1 All medical institutions cannot refuse to treat anyone who is insured by the national health insurance by law and must provide them with unbiased medical services. In Korea, national medical expenses increased from 3.4 trillion won in 1985 to 48.1 trillion won in 2005, that is, rose from 4.0% to 6.0% in terms of national medical expenses versus the national GDP. It was estimated that the national medical expenses would reach 54 trillion won and the ratio 6.4% in 2006.
Most of the materials involved in wound healing fall into the medical device category. Medical treatment materials are divided into 2 categories: reimbursable materials and non-reimbursable materials. This is a vague description, and discussions have been made to clarify the criteria for payment. Medical treatment materials can be covered by a health insurance system when their safety and effectiveness are verified for the diseases wherein not using these materials may impede regular business and/or daily life. It has to be used for the purpose of improving essential functions of the body in a cost-effective manner. If the material is included as a part of the medical treatment service (fee for service), the cost of medical treatment materials has to be included as part of the service cost. 2 It is this vagueness that limits the clinical use of various materials to obtain improved care. For example, foam dressing will be covered only 3 times per week and for only a certain number of weeks regardless of wound character and progress. The rest has to be covered by the patient themselves. It is understandable that scientific guidelines can be very difficult to execute practically but measures have to be made to improve the wound itself based on the efficacy of the device and treatment protocol. Now additional reports that are based on the device-economic study will hopefully provide a logical guideline for reimbursement.
Unlike drugs, medical treatment materials have a smaller market and a shorter life cycle for the products. It is very difficult to assess the device-economic impact based on this short life cycle as well as the fast-changing economy. Reimbursement for products already registered with similar purpose end up having a simpler process but the controversies exist on how to decide the relative purpose and function and cost. 3 Often, new innovated products have difficulty achieving reasonable reimbursement due to vague criteria for purpose of product and thus forfeit their chance to enter the Korean market based on poor reimbursement despite the higher cost of manufacturing. The criteria for purpose should be made clear as products become sophisticated to serve complex problems.
There is no perfect scheme to provide care, especially for wounds. It may lack high-level evidence and often is performed based on knowledge and experience. Not all evidence is double-blind prospective studies. We must start gathering big data to see the efficacy of the treatment and the device. Our role in the future may be working close with the government or international bodies who share this problem. It is also important that academic journals provide a playground to gather these data and come up with an experience-and efficacy-based solution.
